2.

Clinical trials of combination therapies including anti-PD-1/PD-L1 agents in cancer patients

Combination	Phase	Tumor type	Clinical response rate (%)	Reference
PD-1, programmed cell death 1; PD-L1, programmed death 1 ligand; RT, radiation therapy; NSCLC, non-small cell lung cancer.
Nivolumab plus ipilimumab	II	Advanced melanoma	63.8	(125)
	III	Unresectable melanoma	57.6	(126)
Nivolumab plus chemotherapy	I	Advanced NSCLC	54.2	(127)
	II	Advanced and metastatic urothelial carcinoma	19.6	(46)
Pembrolizumab plus chemotherapy	II	Advanced colorectal cancer	53.3	(47)
	II	Advanced gastric cancer	60.0	(48)
Nivolumab plus RT	−	Metastatic melanoma	46.7	(128)